Comparing early and late stent removal after bladder cancer surgery
A Feasibility Randomized Controlled Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
This study is testing whether removing stents earlier or later after bladder cancer surgery helps patients recover better and have fewer complications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Western University, Canada Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (London, Ontario) |
| Trial ID | NCT06595446 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the feasibility of early versus late stent removal in patients undergoing radical cystectomy and ileal conduit formation for bladder cancer. The study aims to determine if the timing of stent removal can impact postoperative complications and recovery. Adult patients who meet the eligibility criteria will be randomly assigned to either early or late stent removal groups. The outcomes will be monitored to assess the effectiveness and safety of each approach.
Who should consider this trial
Good fit: Ideal candidates are adult patients aged 18 and older who are scheduled for radical cystectomy and ileal conduit formation due to bladder cancer.
Not a fit: Patients undergoing treatment without curative intent or those with alternative forms of urinary diversion will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved recovery and reduced complications for bladder cancer patients undergoing surgery.
How similar studies have performed: While there have been studies on stent management in urological surgeries, this specific comparison of early versus late stent removal is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (18 years or older) undergoing radical cystectomy and ileal conduit formation for bladder cancer * Able to give informed written consent to participate. Exclusion Criteria: * Treatment without curative intent (cT4b, salvage or palliative cystectomies); * Patients undergoing alternative forms of urinary diversion (e.g. continent cutaneous urinary diversion or orthotopic neobladder formation) * Patients previously received abdominal/pelvic radiotherapy * Patients with concomitant upper urinary tract cancer
Where this trial is running
London, Ontario
- Victoria Hospital — London, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Kaydee Connors, BSc
- Email: kaydee.connors@lhsc.on.ca
- Phone: 519-685-8500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.